BelongAI Delivers Promising Results at ESMO Congress
Belong.Life has made a noteworthy impact in oncology by showcasing its innovative AI tool, BelongAI Dave – Cancer Mentor, at a recent prestigious event. This important multi-institutional validation study highlights how effectively Dave supports cancer patients.
Overview of the Expert Validation Study
During the European Society for Medical Oncology (ESMO) conference, the study emphasized the expertise of nine senior oncologists. These specialists, known for their extensive experience with various cancer types, thoroughly evaluated the AI mentor's ability to provide relevant information and guidance for cancer management.
In-Depth Evaluation Process
The oncology experts conducted a systematic assessment of Dave's responses to 578 randomly chosen user inquiries. Each response was carefully analyzed for relevance and helpfulness, ensuring alignment with established evidence-based practices. The results were promising, showcasing an impressive validation rating of 91.35% for the AI mentor's relevant recommendations.
Findings by Cancer Group
Although the validation results were largely positive, some minor differences among cancer types were observed. The positive ratings included: Genitourinary (100%), Breast (95.7%), Musculoskeletal (93%), Radiation therapy (88%), Gastrointestinal (87.2%), Pancreatic (87.1%), and Hematological cancers (84%). These findings highlight the reliability of AI recommendations across various cancer groups.
Insights from Experts on AI's Role
Dr. Daniel Vorobiof, a prominent oncologist and Chief Medical Director of Belong.Life, shared his thoughts on the findings, stating that the tools offered by Dave are both valuable and dependable for cancer patients. With these insights, oncologists can better support patients as they navigate their unique cancer journeys.
Company's Commitment to Patient Care
Eliran Malki, co-founder and CEO of Belong.Life, expressed pride in the validation results of the study. He emphasized the company's unwavering commitment to utilizing conversational AI and community engagement to assist patients and enhance health outcomes. This dedication to leveraging advanced technology ensures that patients receive exceptional support.
Global Impact of BelongAI Dave
Since its launch in mid-2023, BelongAI Dave has become an invaluable resource for hundreds of thousands of individuals undergoing cancer treatments around the globe. By providing personalized guidance and 24/7 answers, the platform plays a vital role in improving the overall experience of cancer management.
About Belong.Life
Belong.Life is transforming the healthcare landscape by combining conversational AI, comprehensive data analytics, and meaningful patient communities. The company is recognized for its social and professional networks that empower individuals dealing with cancer as well as conditions like multiple sclerosis. Its foundational platforms are designed to deliver health-grade patient engagement and support.
Enhancing Access and Support
Belong's solutions are crafted to provide extensive support, including access to clinical trials and ongoing educational resources. The platforms adhere to strict privacy standards, ensuring compliance with HIPAA and GDPR, which fosters trust and security among users.
Frequently Asked Questions
What is BelongAI Dave?
BelongAI Dave is an AI-powered cancer mentor that offers personalized guidance and support to cancer patients throughout their treatment journeys.
How was the validation study conducted?
The study involved nine senior oncologists who assessed the responses of BelongAI Dave to a selection of user questions, evaluating relevance and helpfulness based on evidence-based medicine.
What were the results from the oncologists' evaluations?
The evaluations revealed a high validation rate of 91.35% for relevant recommendations, showcasing the effectiveness of the AI mentor as a supportive tool in oncology.
What types of cancer were included in the evaluations?
The evaluations focused on various cancer types, with the highest validation rates found in Genitourinary, Breast, and Musculoskeletal cancers.
What is Belong.Life's mission?
Belong.Life is dedicated to enhancing patient engagement and outcomes through innovative technology, data integration, and active participation within patient communities.